287 related articles for article (PubMed ID: 31814045)
21. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
Tamme K; Oselin K; Kipper K; Tasa T; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
[TBL] [Abstract][Full Text] [Related]
22. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
23. Dosing optimization of meropenem based on a pharmacokinetic analysis in patients receiving hemodiafiltration and an in vitro model.
Yokoyama Y; Nishino K; Matsumoto K; Inomoto Y; Matsuda K; Nakamura RN; Yasuno N; Kizu J
J Infect Chemother; 2018 Feb; 24(2):92-98. PubMed ID: 29054458
[TBL] [Abstract][Full Text] [Related]
24. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
Deshpande P; Chen J; Gofran A; Murea M; Golestaneh L
Nephrol Dial Transplant; 2010 Aug; 25(8):2632-6. PubMed ID: 20181801
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
Bauer SR; Salem C; Connor MJ; Groszek J; Taylor ME; Wei P; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2012 Mar; 7(3):452-7. PubMed ID: 22282479
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
[TBL] [Abstract][Full Text] [Related]
28. Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.
Keough LA; Krauss A; Hudson JQ
Int J Clin Pharm; 2018 Oct; 40(5):1250-1256. PubMed ID: 30051232
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis.
Oliveira MS; Machado AS; Mendes ET; Chaves L; Perdigão Neto LV; Vieira da Silva C; Cavani Jorge Santos SR; Sanches C; Macedo E; Levin AS
Clin Ther; 2020 Apr; 42(4):625-633. PubMed ID: 32199609
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
[TBL] [Abstract][Full Text] [Related]
31. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang SM; Lewis SJ; Rhie SJ
J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
[TBL] [Abstract][Full Text] [Related]
32. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
33. Survey of pharmacists’ antibiotic dosing recommendations for sustained low-efficiency dialysis.
Mei JP; Ali-Moghaddam A; Mueller BA
Int J Clin Pharm; 2016 Feb; 38(1):127-34. PubMed ID: 26499505
[TBL] [Abstract][Full Text] [Related]
34. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
[TBL] [Abstract][Full Text] [Related]
35. Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae.
Gould M; Ginn AN; Marriott D; Norris R; Sandaradura I
Int J Antimicrob Agents; 2019 Aug; 54(2):240-244. PubMed ID: 31108222
[TBL] [Abstract][Full Text] [Related]
36. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.
Oh KH; Kim C; Lee H; Lee H; Jung JY; Kim NJ; Yu KS; Shin KH; Jang IJ; Ahn C
Antimicrob Agents Chemother; 2009 Aug; 53(8):3266-8. PubMed ID: 19451284
[TBL] [Abstract][Full Text] [Related]
38. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
Zander J; Döbbeler G; Nagel D; Maier B; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
Crit Care; 2016 Apr; 20():79. PubMed ID: 27039986
[TBL] [Abstract][Full Text] [Related]
39. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M
J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963
[TBL] [Abstract][Full Text] [Related]
40. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
